Accession Therapeutics Marks Milestone with TROCPT-01 Clinical Trial Initiation in Cancer Treatment Accession Therapeutics has successfully dosed its first patient in a Phase 1 trial for TROCEPT-01, a novel cancer immunotherapy designed to enhance treatment efficacy.

Accession Therapeutics Marks Milestone with TROCPT-01 Clinical Trial Initiation in Cancer Treatment #United_Kingdom #Oxford #Cancer_Immunotherapy #Accession_Therapeutics #TROCEPT-01